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Abstract
Background
Left ventricular non-compaction (LVNC) is a rare cardiomyopathy. Many
genetic variants have been associated with LVNC. However, the number of the
previous LVNC-associated variants that are common in the background popu-
lation remains unknown. The aim of this study was to provide an updated list
of previously reported LVNC-associated variants with biologic description and
investigate the prevalence of LVNC variants in healthy general population to
find false-positive LVNC-associated variants.
Methods and Results
The Human Gene Mutation Database and PubMed were systematically searched
to identify all previously reported LVNC-associated variants. Thereafter, the
Exome Sequencing Project (ESP) and the Exome Aggregation Consortium
(ExAC), that both represent the background population, was searched for all
variants. Four in silico prediction tools were assessed to determine the func-
tional effects of these variants. The prediction results of those identified in the
ESP and ExAC and those not identified in the ESP and ExAC were compared.
In 12 genes, 60 LVNC-associated missense/nonsense variants were identified.
MYH7 was the predominant gene, encompassing 24 of the 60 LVNC-associated
variants. The ESP only harbored nine and ExAC harbored 18 of the 60 LVNC-
associated variants. In total, eight out of nine ESP-positive variants overlapped
with the 18 variants identified in ExAC database.
Conclusions
In this article, we identified 9 ESP-positive and 18 ExAC-positive variants of 60
previously reported LVNC-associated variants, suggesting that these variants are
not necessarily the monogenic cause of LVNC.
Introduction
Left ventricular non-compaction (LVNC) is a rare
cardiomyopathy with a prevalence that varies considerably
among studies (0.014–14%) (Oechslin et al. 2000;
Pignatelli et al. 2003; St€ollberger and Finsterer 2005; Aras
et al. 2006; Belanger et al. 2008; Stanton et al. 2009; Tian
et al. 2014). Left ventricular non-compaction is most
likely caused by a pathological arrest in the compaction
process, which leads to a non-compacted left ventricular
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myocardium (Dusek et al. 1975; Chin et al. 1990; Agmon
et al. 1999; Zambrano et al. 2002). Left ventricular
non-compaction is characterized by a non-compacted
inner myocardial layer and a compacted outer myocardial
layer with deep intratrabecular recesses, that are commu-
nicated to the left ventricular chamber (Jenni et al. 2001;
Sarma et al. 2010).
There are no single diagnostic criteria for LVNC. The
clinical presentation is highly variable from asymptomatic
to symptomatic with heart failure (HF), atrial and ven-
tricular arrhythmias, thromboembolic events, and sudden
cardiac death (Ichida et al. 1999; Paterick et al. 2010;
Bhatia et al. 2011). Left ventricular non-compaction is
associated with congenital cardiac disorders, other car-
diomyopathies, and some neuromuscular diseases (Jenni
et al. 2001).
Both sporadic and familial LVNC have been reported
(Sasse-Klaassen et al. 2003; Sen-Chowdhry and McKenna
2008). The pattern of familial LVNC inheritance is
mainly autosomal dominant with incomplete penetrance,
although autosomal recessive and X-linked inheritance
have been reported (Bleyl et al. 1997a; Sasse-Klaassen
et al. 2003; Xing et al. 2006; Sen-Chowdhry and
McKenna 2008). Left ventricular non-compaction is
associated with variants in mitochondrial, cytoskeletal,
Z-line, and sarcomeric genes (Sen-Chowdhry and
McKenna 2008). The sarcomeric genes include cardiac
b-myosin heavy chain (MYH7), cardiac troponin T
(TNNT2), and cardiac a-actin (ACTC1) (Budde et al.
2007; Hoedemaekers et al. 2007; Monserrat et al. 2007;
Klaassen et al. 2008). Furthermore, LVNC has been
described with variants in tafazzin (TAZ), alpha-dystro-
brevin (DTNA), tropomyosin 1 (TPM1), and cardiac
troponin I (TNNI3) (Ichida et al. 2001; Budde et al.
2007; Klaassen et al. 2008; Probst et al. 2011; Arndt
et al. 2013). Carriers of these sarcomeric variants
demonstrate a range of phenotypes from no LVNC
(asymptomatic) to early onset LVNC or other cardiomy-
opathies (Moric-Janiszewska and Markiewicz-Łoskot
2008; Finsterer 2009).
The first gene associated with LVNC, tafazzin, was
reported more than 17 years ago (Bleyl et al. 1997a).
Ongoing genetic research has since discovered many novel
variants in the genes described above. Despite the known
associated genes, the genetic background of this car-
diomyopathy is not fully understood.
The aim of this article was to provide an updated
list of LVNC-associated variants previously reported in
the literatures with biologic description. In addition, we
will investigate the prevalence of LVNC variants in a
healthy general population in order to identify false-
positive LVNC-associated variants.
Methods
Data collection
Genes and variants previously associated with LVNC were
identified using the Human Gene Mutation Database
(HGMD) and by reviewing published literature in
PubMed until July 17th 2015 (HGMD (Human Gene
Mutation Database for Human Genetics Research);
Exome Variant Server).
The following queries were used: ((Left ventricular
non-compaction), (Left ventricular noncompaction), (left
ventricular hypertrabeculation) and (left ventricular
hypertrabecular/non-compaction [Mesh])) and ((Genetic)
or (“Genetics” [Mesh])), in order to collect all published
data on identified LVNC-associated variants. Further-
more, we also searched HGMD, Google scholar, and pub-
licly available databases.
All relevant articles were reviewed for data on func-
tional studies and on familial co-segregation. We defined
co-segregation as at least two genotypically positive family
members with the same phenotype. Positive functional
data were determined as any in vivo or in vitro model
demonstrating results differing from the wild-type model
as described previously.
Exome sequencing project
In the Exome Sequencing Project (ESP), next-generation
sequencing of all protein coding regions in 6503 individ-
uals of African American (n = 2203 individuals) and
European American (n = 4300 individuals) descent from
different population studies has been carried out. Clini-
cal data were not readily available or available on
request.
The ESP database was searched for the missense and
nonsense variants previously associated with LVNC.
Left ventricular non-compaction-associated variants
were subdivided into those that were identified in the
ESP database (ESP positive) and those that were not
identified in the ESP database (ESP negative).
The exome aggregation consortium
In the exome aggregation consortium, sequenced 60,706
unrelated individuals on the regions of the human gen-
ome that encode proteins as part of various disease-speci-
fic and population genetic studies. Individuals with sever
pediatric disease have been removed. Thus, the ExAC
Browser is a very useful dataset of allele frequencies. Left
ventricular non-compaction-associated variants were
subdivided into those that were identified in the ExAC
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database (ExAC positive) and those that were not
identified in the ExAC database (ExAC negative).
Prediction analysis
The functional effects of all variants were assessed using
four prediction tools: (1) Conservation across species; (2)
Grantham Score; (3) Sorting Intolerant From Tolerant,
v5.1.1 (SIFT); and (4) PolyPhen-2. Conservation across
species was obtained from the HGMD and classified as
occurring at a position with no substitutions (conserved/
pathogenic) or ≥1 substitutions (not conserved/benign).
Grantham physicochemical values were calculated using
the Grantham amino acid difference matrix. We defined a
value above 100 as radical (pathogenic) and a value under
100 as conservative (benign) (Grantham 1974; Giudicessi
et al. 2012). Using PolyPhen-2, each variant was labeled
as “probably damaging,” “possibly damaging,” or “be-
nign” (PolyPhen-2). Variants labeled “probably damag-
ing” and “possibly damaging” were considered to be
“damaging” (pathogenic) in our analysis. Finally, SIFT
prediction classified variants as “tolerant” (benign) or
“damaging” (pathologic) (SIFT).
In a final analysis using all prediction tools, a variant
was considered damaging (pathogenic) if ≥3 in silico pre-
diction tools identified the variant as pathogenic, as previ-
ously described (Giudicessi et al. 2012; Andreasen et al.
2013; Jabbari et al. 2013; Risgaard et al. 2013). Variants
predicted to be damaging by one or two tools were con-
sidered to be variants of uncertain significance (VUS).
Each of the four prediction tools predicted separately the
pathogenicity of previously published LVNC-associated
variants. We used Giudicessi et al. (2012) agreement of
≥3 in silico tool predictions to assess the pathogenic sta-
tus of a LVNC-associated variant. This is an established
and robust bioinformatics method, increasing the impor-
tance of the assessment using the known online predic-
tion tools. (Giudicessi et al. 2012; Andreasen et al. 2013;
Jabbari et al. 2013; Risgaard et al. 2013) This method
increases the correlation between genetic findings and
clinical practice especially in rare diseases.
Results
Through a review of the literature, we identified 12 genes
previously associated with LVNC (Table S1). Overall, we
identified 60 missense/nonsense variants previously associ-
ated with LVNC, and most of the variants (40%) were
found in MYH7 (24 out of 60).
The ESP database included 9 of these 60 variants,
which were found in seven genes: MYBPC3, MYH7B,
MIB, TNNT2, CASQ2, TAZ, and LDB3 (Table S1).
Notably, no variants in MYH7 were found in the ESP
database. In the ExAC database, we identified 18 variants
distributed in all genes except TPM1. In total, eight out
of nine ESP-positive variants overlapped with the 18 vari-
ants identified in ExAC database (Table S1).
Two variants (p.D545N and p.D955N) coexisted as a
heterozygous double mutation in the cis position on the
same MYH7 allele segregating with LVNC. Notably, the
patients were of various ethnic backgrounds and national-
ities from Europe, America, and Asia. Most of the
patients were men, and the patient age spectrum was
widespread from infancy to adulthood.
Heredity pattern
In total, we found 42 familial forms of LVNC. Familial
genetic co-segregation was found in 30 out of 42 clinical
familial cases (Table S1). Some of these variants were
also identified in other studies not having a clear hered-
ity pattern, suggesting a sporadic form of LVNC. There-
p.F252L
p.R281T
p.L301Q
p.R369Q
p.D545N
p.D955N
p.R1250W
p.R1359C
p.A1766T
p.L658Vp.I818N
p.Y1488C
p.R1925G
p.R243H
p.Y350N
p.Y283D
p.Y266*
p.L390P
p.M531R
p.C905R
p.N1918K
p.E929K
p.R249G
p.M439R
Figure 1. LVNC-associated variants in the MYH7 exons. White exons are untranslated region and blue exons are translated sequence.
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fore, there is some overlap between familial and sporadic
cases.
In the familial cases, three heredity patterns, including
autosomal dominant, autosomal recessive, and X-linked,
were reported. The majority of the heredity patterns
were autosomal dominant. We found only one
example of autosomal recessive inheritance pattern
among all familial cases (p.R820W/MYBPC3). Some vari-
ants showed both sporadic and familial inheritance pat-
terns in different studies (p.G197R/TAZ) (Bleyl et al.
1997b).
Phenotypes of the families
We found a wide clinical spectrum of LVNC phenotypes
ranging from asymptomatic to symptomatic (Table S1).
Left ventricular non-compaction was the predominant
form of cardiomyopathy in the families (39 of 41). How-
ever, in some families, the relatives showed other car-
diomyopathies (dilated cardiomyopathy (DCM) and
hypertrophic cardiomyopathy (HCM)) with no sign of
LVNC (Table S1). There were also four families with co-
existing LVNC and DCM, and two families showed
LVNC and HCM, and one family exhibited LVNC and a
congenital heart defect (Ichida et al. 2001). Notably, we
found two cases with several types of cardiac diseases in
their families (Postma et al. 2011; Ronvelia et al. 2012).
In a family with the TAZ/p.G195* variant, LVNC co-
existed with Barth syndrome, DCM, atrial septal defect,
and elevated urine 3-methylglutaconic acid (3-MGA)
levels (Ronvelia et al. 2012). Lastly, LVNC co-existed with
cardiovascular malformation and Ebstein᾿s anomaly in a
family with the MYH7/p.Y283D variant (Postma et al.
2011). These results highlighted that multiple factors
affect the pathogenicity of variants, but family-based
whole-genome sequencing makes it possible to identify
the association between a genetic variant and a rare
disease.
Prediction analysis
Prediction analysis was carried out for 56 of the 60 vari-
ants. The remaining four variants were not analyzed
because they generated stop codons.
By utilizing the Giudicessi et al. (2012) agreement of
≥3 in silico tools, prediction analysis determined that
51% of missense variants were pathogenic, 41% were
VUS, and 5% were benign. The pathogenicity of the
p.D626N/LDB3 variant could not be predicted using the
agreement of ≥3 in silico tools and it did not match with
the amino acids in six isoforms of the protein.
Finally, by using the Giudicessi et al. (2012) agreement
of ≥3 in silico tools, 44% (4/9) of the ESP-positive
variants were pathogenic compared with 55% (10/18) of
the ExAC-positive variants (Table S1).
Discussion
Using bioinformatics, this is the first study to identify
and investigate, all previous genetic variants associated
with LVNC until July 2015. We found 60 variants in 12
genes associated with LVNC. In addition, prediction anal-
yses were carried out for all missense variants.
This study identified 9 LVNC-associated variants in the
ESP database and 18 variants in ExAC database.
In the MYH7 gene, 24 of 60 LVNC-associated variants
were reported. None of those were identified in the ESP,
but two SNPs (p.R1359C and p.R243H) were identified in
ExAC database (Klaassen et al. 2008). These two variants
predicted to be pathogenic with agreement of more than
three prediction tools analysis. The assumption is that a
pathogenic variant is unlikely to be present in a high num-
ber of individuals in the background population. The cut-
off for how many persons, one variant can be present in a
cohort like ESP and still be pathogenic, is still unclear.
Also, it should be kept in mind that it is of course possible
that the geno-positive individuals in general population
can develop LVNC or other cardiomyopathies in late age.
The p.R1359C variant in MYH7 was a sporadic case of
LVNC, while the p.R243H was identified with family co-
segregation and with low allele frequency (0.000008236) in
the ExAC database (Exome Aggregation Consortium
(ExAC)). These findings suggest that the p.R243H theoret-
ically develop LVNC in healthy carriers. Family co-segre-
gation is a valuable tool for determining the pathogenicity
of disease-causing variants (Klaassen et al. 2008). Hoede-
maekers et al. (2010) performed a family screening with
both molecular and clinical examinations in 58 patients
with LVNC and their 194 family members. This screening
revealed that 67% (39/58 patients with LVNC) had a
genetic background with these variants. Furthermore, nine
of 50 families had one of these variants. The findings sup-
port that the variants in MYH7 penetrate to the next gen-
eration. Budde et al. (2007) assessed the clinical and
molecular characterization of a large German family with
LVNC. The variant p.R281T in MYH7 was present in
affected family members (11/24) and also the p.R281T
known as ESP-negative and ExAC-negative variant. These
results supported the major role of MYH7 variants in the
development of LVNC.
Kaneda et al. (2008) screened 99 unrelated probands
with DCM and five probands with isolated LVNC and
reported a novel p.M531R variant in MYH7 in a patient
with isolated LVNC, and we did not find the p.M531R in
ESP and ExAC databases. To define the function of the
p.M531R variant in MYH7, Kaneda et al. (2008) per-
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formed a functional study with transgenic mouse carrying
the p.M532R mutant alpha MHC gene, which is identical
to the p.M531R variant in human beta MHC. Although
none of the mice had the characteristics of LVNC, 50–
70% of the transgenic mice demonstrated left ventricular
hypertrophy at 2–3 months of age. In addition, dilation
of the left ventricle was reported in approximately 25% of
transgenic mice by 18 months of age. They showed
biphasic changes in the LV wall thickness (HCM develop-
ing to DCM). Their results suggested that the p.M531R
variant has a malignant or pro cardiomyopathic effect on
cardiac function.
By using four prediction analysis, 17 out of 24 (71%)
previously reported LVNC-associated MHY7 variants were
predicted pathogenic, and interestingly, none of variants
in MYH7 were predicted benign. Due to the effect of
LVNC-associated variants in MYH7 on cardiac develop-
ment and function, the genetic basis of this gene in
LVNC appears to be important. The variants found in
MYH7 in patients with isolated LVNC strongly support
the importance of this gene in pathogenesis of LVNC.
Functional investigations of these variants are important
and needed to provide a more comprehensive under-
standing of the effects of variants on protein function.
We identified LVNC-associated genes (DTNA, MYH7B
and CASQ2) that had only one nonsynonym LVNC-
associated variant (p.P121L, p.R890C, and p.H244R)
(Ichida et al. 2001; Hoedemaekers et al. 2010; Esposito
et al. 2013). The p.H244R and p.R890C variants present
in both ESP and ExAC database, and the p.P121L vari-
ant only present in ExAC database. In all of these vari-
ants, there was family co-segregation with the same
phenotype (LVNC) (Ichida et al. 2001; Hoedemaekers
et al. 2010; Esposito et al. 2013). The genetic screening
in the first degree relatives to identify co-segregation is
an important tool to determine the pathogenicity of a
variant. These co-segregation data suggest that these vari-
ants are likely to be disease causing in a monogenic pat-
tern, while they are predicted benign, VUS, and
pathogenic (Table S1).
MYBPC3 contains seven LVNC-associated variants, of
which three (p.G5R, p.G490R and p.R502W) are found in
the ESP database and six variants (p.R820W, p.P873L,
p.G5R, p.G490R, p.G148R, and p.R502W) identified in
ExAC Browser (Table S1). Interestingly, p.R820W exhib-
ited autosomal recessive inheritance, whereas the rest dis-
played autosomal dominant inheritance. The p.G490R
and the p.R502W predicted as pathogenic variants, while
they are present in both ESP database and ExAC database.
These variants were also identified in a family co-segrega-
tion study. The family members with the p.R502W devel-
oped HCM and the family member with the p.G490R
developed LVNC. These data point to the fact that there
are many factors (for example modifier genes, age, envi-
ronment, etc.) that affect the pathogenicity of variants.
Functional studies are often helpful to clarify the func-
tion of the protein variants such as rare and low-fre-
quency LVNC-associated variants. Functional studies have
been performed for eight LVNC-associated variants
(MYH7/p.M531R, MIB1/p.R530*, and p.V943F, PRDM16/
p.K702*, TNNT2/p.E96K ,and p.R131W, LDB3/p.D117N,
and TPM1/p.D84N). All variants showed loss-of-function
in mutated proteins (Table S1).
Accurate estimating of rare variants frequency in back-
ground population is needed with a widespread ethnic
background population with enormous number of
healthy individuals. Multiple factors (e.g., modifier genes,
age, environment, etc.) affect the penetrance of patho-
genic variants in healthy individuals. Thus, it is not possi-
ble to determine the possibility of pathogenicity for
ExAC-positive variant. Additional functional study and
genetic searching in family members are needed to clarify
the pathogenic effect of these ExAC-positive variants in
general population.
Limitations
One limitation of this study is that the variants reported
in this manuscript were collected in patients of different
nationalities worldwide, while the ESP is restricted to
European American and African American patients. Thus,
the prevalence of LVNC in individual carrying LVNC-
associated variants in the ESP and ExAC could not been
determined.
Due to lack of data regarding variants positioned in
promoters, introns, and untranslated regions (UTR) in
the ESP, variants found in these regions were not
included in our study. The clinical status of variant carri-
ers was not readily available. It is possible that some of
individuals suffer from LVNC or other cardiomyopathies
in the ExAC population.
Functional investigations have only been carried out
for a minority of the variants, and not all studies investi-
gated whether a variant co-segregated.
Implications
This novel dataset should be used in the evaluation of
potential disease-causing variants. The presence of a
potential disease-causing variant in these large databases
implies that the variant is less likely to be disease causing.
The presence of a variant in one person in the large data-
bases (more than 5000 persons) does not rule out disease
causality, but in our opinion, the presence of a variant in
more than five persons makes it unlikely to be
pathogenic.
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Conclusions
In this analysis, we demonstrate that MYH7 is the pre-
dominant gene associated with LVNC. MYH7 variants
comprised 24 of the total 60 variants. None of these
variants were found in the ESP, but two of the variants
were found in the ExAC database. Family members
showed a widespread clinical spectrum from asymp-
tomatic to symptomatic forms of LVNC and other
cardiomyopathies.
We also identified nine ESP-positive and 18 ExAC-
positive variants of 60 previously reported LVNC-asso-
ciated variants, suggesting that these variants are not nec-
essarily the monogenic cause of LVNC. Thus, additional
data from functional studies and genetic screening in
family members is still important in order to help clini-
cian to estimate whether a variant is truly disease causing
or not.
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